SCHEMBL23217206

SCHEMBL23217206

COCOc1c(C=O)cc(Br)c2occc12

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.37
KCNA3 P22001 7/20 0.35
KCNA2 P16389 2/20 0.35
KCNA4 P22459 1/20 0.34
KCNA5 P22460 1/20 0.34
KCNA1 Q09470 1/20 0.34
KCNH2 Q12809 1/20 0.34
CYP1A1 P04798 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP1B1 Q16678 2/20 0.34
CYP3A4 P08684 2/20 0.34
LMNA P02545 1/20 0.34
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34
ABCB1 P08183 1/20 0.34
MAPT P10636 1/20 0.34
ALDH1A1 P00352 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23217746 0.86 NLRP3 (0.43) PTPN1KCNA3CYP1A1CYP1A2CYP1B1
SCHEMBL23217709 0.82 PTGDR2 (0.46) PTPN1KCNA3KCNA2KCNA5KCNA1
SCHEMBL21468873 0.81 ALDH1A1 (0.36) PTPN1KCNA2CYP1A2CYP3A4LMNA
SCHEMBL19775924 0.81 ALDH1A1 (0.36) PTPN1KCNA2CYP1A2CYP3A4LMNA
SCHEMBL29481725 0.81 ALDH1A1 (0.36) PTPN1KCNA2CYP1A2CYP3A4LMNA
SCHEMBL23217221 0.80 PTPN1 (0.38) PTPN1KCNA3KCNA2CYP1A1CYP1A2
SCHEMBL23217850 0.79 GRM2 (0.34) KCNA3KCNA2KCNA4KCNA5KCNA1
SCHEMBL23217471 0.79 KCNA2 (0.39) KCNA3KCNA2KCNA4KCNA5KCNA1
SCHEMBL23217654 0.78 ALDH1A1 (0.38) KCNA3KCNA2KCNA4KCNA5KCNA1
SCHEMBL30973476 0.77 ADORA3 (0.41) KCNA3KCNA2KCNA5CYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-09-04 US disclosed
CN-114555570-B Oral complement factor D inhibitors 拜奥克里斯特制药公司 2024-09-13 CN disclosed
EP-4041717-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114555570-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-27 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275991-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PTPN1 3535/4885KCNA3 4001/4885KCNA2 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.